Injectable PrEP
Resource Hub
PrEP is short for pre-exposure prophylaxis. It is the use of antiretroviral medication to prevent getting HIV. PrEP is used by people without HIV who may be exposed to HIV through sex or injection drug use.
What’s Next? PrEPping for Injectables
Implementing Injectable PrEP at your Agency
Injectable PrEP Approved in December 2021!
Cabotegravir (Brand Name Apretude) became available for use as PrEP in 2021. This new form of PrEP builds on the oral tablets taken daily, with an injectable form of prevention, given by injection every 2 months.
Injectable PrEP: What It’s All About
August 15, 2023
Event Slides & Resources
Webinar Slides
(.pdf)
Download →
Injectable PrEP Pocket Card
(.pdf)
Download →
Optimizing PrEP Adherence
(.pdf)
Download →
Implementing Injectable PrEP: Lessons From The Field
September 19, 2023
View The Spanish Language Version →
Event Slides & Resources
Injectable HIV PrEP Workflow
(.pdf)
Download →
New York Knows Injectable PrEP Learning Collaborative
(.pdf)
Download →
California PTC Learning Collaborative
(.pdf)
Download →
Financing Injectable PrEP: Strategies and
Lessons Learned
October 17, 2023
Listen To The Spanish Language Version →
Event Slides & Resources
Webinar Slides
(.pptx)
Download →
Long Acting Injectable PrEP Financing Considerations
(.pdf)
Download →
Washington University St. Louis PrEP Clinic
(.pdf)
Download →
About The Webinar Series
The PS19-1904 Track B Capacity Building Assistance providers of Washington University in St. Louis, Latino Commission on AIDS, University of Rochester, and San Francisco Department of Public Health will hosted a four-part virtual series that addressed injectable PrEP. Cabotegravir was approved for HIV PrEP in December 2021, but implementation and uptake have been low. The purpose of this series is to build the capacity of the HIV workforce for injectable PrEP implementation throughpeer-to-peer learning. This series is for agencies at any stage of implementation.